Bone Biologics (NASDAQ:BBLG) Posts Earnings Results, Misses Expectations By $0.04 EPS

Bone Biologics (NASDAQ:BBLG) announced its quarterly earnings results on Friday. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.04), FiscalAI reports.

Bone Biologics Stock Performance

BBLG stock opened at $0.66 on Friday. The business’s 50-day moving average is $1.18 and its two-hundred day moving average is $1.25. The company has a market cap of $1.19 million, a price-to-earnings ratio of -0.48 and a beta of 0.92. Bone Biologics has a fifty-two week low of $0.62 and a fifty-two week high of $4.13.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bone Biologics in a report on Friday, July 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Trading of Bone Biologics

A hedge fund recently raised its position in Bone Biologics stock. DRW Securities LLC grew its holdings in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,576 shares of the company’s stock after acquiring an additional 12,549 shares during the period. DRW Securities LLC owned about 1.31% of Bone Biologics worth $34,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 34.30% of the stock is owned by institutional investors and hedge funds.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.